Dr. Yana Puckett, MD
Claim this profileNancy N and JC Lewis Cancer & Research Pavilion St. Joseph's/Candler
Studies Skin Cancer
Studies Melanoma
3 reported clinical trials
6 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage II
Stage III
2Melanoma
Stage IV
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Yana Puckett, MD is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Surgical Excision Margins
for Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Recruiting2 awards Phase 39 criteria
More about Yana Puckett, MD
Clinical Trial Related8 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Yana Puckett, MD has experience with
- Wide Local Excision = 2cm Margin
- Wide Local Excision = 1cm Margin
- Pembrolizumab
- Ipilimumab
- Nivolumab
- Sargramostim
Breakdown of trials Yana Puckett, MD has run
Skin Cancer
Melanoma
Cutaneous Melanoma
Merkel Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yana Puckett, MD specialize in?
Yana Puckett, MD focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage II.
Is Yana Puckett, MD currently recruiting for clinical trials?
Yes, Yana Puckett, MD is currently recruiting for 2 clinical trials in Savannah Georgia. If you're interested in participating, you should apply.
Are there any treatments that Yana Puckett, MD has studied deeply?
Yes, Yana Puckett, MD has studied treatments such as Wide Local Excision = 2cm Margin, Wide Local Excision = 1cm Margin, Pembrolizumab.
What is the best way to schedule an appointment with Yana Puckett, MD?
Apply for one of the trials that Yana Puckett, MD is conducting.
What is the office address of Yana Puckett, MD?
The office of Yana Puckett, MD is located at: Nancy N and JC Lewis Cancer & Research Pavilion St. Joseph's/Candler, Savannah, Georgia 31405 United States. This is the address for their practice at the Nancy N and JC Lewis Cancer & Research Pavilion St. Joseph's/Candler.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.